Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

Recent health news highlights include a UK hospital-related death due to a cyberattack, Walgreens beating profit estimates ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema ...